SCHEMBL2556475

SCHEMBL2556475

FC[C@H]1CO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL93299 1.00
SCHEMBL7423636 1.00
Ethylene SCHEMBL10802720 0.93
Oxirane SCHEMBL10796207 0.90
Propylene Oxide SCHEMBL10792620 0.87
SCHEMBL18652809 0.76
SCHEMBL8347293 0.72
SCHEMBL1703680 0.72
SCHEMBL7527882 0.67
SCHEMBL7524613 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1673377-B1 PROCESS FOR THE PREPARATION OF 3-AMINO-2-HYDROXYPROPYLPHOSPHINIC ACID DERIVATIVES AVENTIS PHARMA INC (US) 2013-12-25 EP claimed
JP-4558732-B2 2010-10-06 JP claimed
JP-2007506747-A 2007-03-22 JP claimed
US-7186705-B2 Process for the preparation of 3-amino-2-hydroxypropylphosphinic acid derivatives AVENTIS PHARMACEUTICALS INC. (US) 2007-03-06 US claimed
EP-1673377-A1 PROCESS FOR THE PREPARATION OF 3-AMINO-2-HYDROXYPROPYLPHOSPHINIC ACID DERIVATIVES Aventis Pharmaceuticals Inc. (US) 2006-06-28 EP claimed
WO-2005030781-A1 PROCESS FOR THE PREPARATION OF 3-AMINO-2-HYDROXYPROPYLPHOSPHINIC ACID DERIVATIVES AVENTIS PHARMACEUTICALS INC. (US) 2005-04-07 WO claimed
US-20050070507-A1 Process for the preparation of 3-amino-2-hydroxypropylphosphinic acid derivatives AVENTIS PHARMACEUTICALS INC. (US) 2005-03-31 US claimed
EP-3292114-B1 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO ARENA PHARM INC (US) 2020-03-11 EP disclosed
CN-108174603-A 1-heteroaryl-indoline-4-carboxamides as GPR52 modulators for the treatment or prevention of disorders related thereto 阿芮纳制药有限公司 2018-06-15 CN disclosed
EP-3292114-A1 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2018-03-14 EP disclosed
US-9676758-B2 1-heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto Arena Pharmaceutical, Inc. (US) 2017-06-13 US disclosed
US-20170096441-A1 PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-04-06 US disclosed
WO-2016176571-A1 1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2016-11-03 WO disclosed
EP-2558466-A2 PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS The Regents of the University of California (US) 2013-02-20 EP disclosed
US-20130029940-A1 PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-01-31 US disclosed
WO-2011130557-A2 PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-10-20 WO disclosed
US-7186705-B2 Process for the preparation of 3-amino-2-hydroxypropylphosphinic acid derivatives AVENTIS PHARMACEUTICALS INC. (US) 2007-03-06 US disclosed
EP-1673377-A1 PROCESS FOR THE PREPARATION OF 3-AMINO-2-HYDROXYPROPYLPHOSPHINIC ACID DERIVATIVES Aventis Pharmaceuticals Inc. (US) 2006-06-28 EP disclosed
WO-2005030781-A1 PROCESS FOR THE PREPARATION OF 3-AMINO-2-HYDROXYPROPYLPHOSPHINIC ACID DERIVATIVES AVENTIS PHARMACEUTICALS INC. (US) 2005-04-07 WO disclosed
US-20050070507-A1 Process for the preparation of 3-amino-2-hydroxypropylphosphinic acid derivatives AVENTIS PHARMACEUTICALS INC. (US) 2005-03-31 US disclosed